A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85704, United States
Denver, Colorado 80218, United States
Tampa, Florida 33612, United States
Kettering, Ohio 45409, United States
Portland, Oregon 97213, United States
Dallas, Texas 75201, United States
The Woodlands, Texas 77380, United States
Tyler, Texas 75702, United States
Yakima, Washington 98902, United States
Orbassano, 10043, Italy
Seoul, 138-736, South Korea
Taichung, 407, Taiwan